1. Repositório Institucional da Universidade Federal de Sergipe - RI/UFS
  2. PRODUÇÃO CIENTÍFICA
  3. DFS - Departamento de Fisiologia
  4. DFS - Artigos de periódicos
Use este identificador para citar ou linkar para este item: https://ri.ufs.br/jspui/handle/riufs/24156
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBotelho, Marco Antonio-
dc.contributor.authorQueiroz, Dinalva Brito-
dc.contributor.authorBarros, Gisele-
dc.contributor.authorGuerreiro, Stela-
dc.contributor.authorFechine, Pierre-
dc.contributor.authorUmbelino, Sonia-
dc.contributor.authorLyra, Arão-
dc.contributor.authorBorges, Boniek-
dc.contributor.authorFreitas, Allan-
dc.contributor.authorQueiroz, Danilo Caldas de-
dc.contributor.authorRuela, Ronaldo-
dc.contributor.authorAlmeida, Jackson Guedes-
dc.contributor.authorQuintans Junior, Lucindo-
dc.date.accessioned2026-01-08T17:35:50Z-
dc.date.available2026-01-08T17:35:50Z-
dc.date.issued2014-02-
dc.identifier.citationBOTELHO, M. A. et al. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics, São Paulo, v. 69, n. 2, p. 75-82, fev. 2014. Disponível em: https://www.scielo.br/j/clin/a/xtwXWHWXjDVX4sZKVgVSyTM/abstract/?lang=en. Acesso em: 8 jan. 2026.pt_BR
dc.identifier.issn1980-5322-
dc.identifier.urihttps://ri.ufs.br/jspui/handle/riufs/24156-
dc.languageengpt_BR
dc.publisherFaculdade de Medicina da Universidade de São Paulopt_BR
dc.relation.ispartofClinicspt_BR
dc.subjectNanotechnologypor
dc.subjectConfocal Raman spectroscopypor
dc.subjectTransdermal deliverypor
dc.subjectMenopausepor
dc.subjectHormone therapypor
dc.subjectNanoparticlespor
dc.titleNanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy studypt_BR
dc.typeArtigopt_BR
dc.identifier.licenseCreative Commons Atribuição 4.0 Internacional (CC BY 4.0)pt_BR
dc.description.resumoOBJECTIVE: To determine the safety and efficacy of a transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%) for relieving postmenopausal symptoms. METHODS: A total of 66 postmenopausal Brazilian women with climacteric symptoms of natural menopause received transdermal nanostructured formulations of progesterone and estrogens in the forearm daily for 60 months to mimic the normal ovarian secretory pattern. Confocal Raman spectroscopy of hormones in skin layers was performed. Clinical parameters, serum concentrations of estradiol and follicle-stimulating hormone, blood pressure, BI-RADS classification from bilateral mammography, and symptomatic relief were compared between baseline and 60 months post-treatment. Clinicaltrials.gov: NCT02033512. RESULTS: An improvement in climacteric symptoms was reported in 92.5% of women evaluated before and after 60 months of treatment. The serum concentrations of estradiol and follicle-stimulating hormone changed significantly (p,0.05) after treatment; the values of serum follicle-stimulating hormone decreased after 60 months from 82.04¡4.9 to 57.12¡4.1 IU/mL. A bilateral mammography assessment of the breasts revealed normal results in all women. No adverse health-related events were attributed to this hormone replacement therapy protocol. CONCLUSION: The nanostructured formulation is safe and effective in re-establishing optimal serum levels of estradiol and follicle-stimulating hormone and relieving the symptoms of menopause. This transdermal hormone replacement therapy may alleviate climacteric symptoms in postmenopausal women.pt_BR
dc.description.localSão Paulo, SPpt_BR
Aparece nas coleções:DFS - Artigos de periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
NanostructuredTransdermalHormoneReplacementTherapy.pdf2,83 MBAdobe PDFThumbnail
Visualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.